implitapide
Peptideexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2003 (NCT00079846)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
Microsomal triglyceride transfer protein inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(C)c2c3ccccc3n(Cc3cccc([C@@H](C(=O)N[C@@H](CO)c4ccccc4)C4CCCC4)c3)c2n1- Mol. weight
- 531.7 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2105804 ↗
Also known as
- (2s)-2-cyclopentyl-2-(4-((2,4-dimethyl-9h-pyrido(2,3-b)indol-9-yl)methyl)phenyl)-n-((1s)-2-hydroxy-1-phenylethyl)ethanamide
- aegr427
- implitapide
- implitapide
- implitapide
- implitapide
- implitapide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00080132 | Phase 2 | Oct 1, 2004 | Medical Research Laboratories International |
| NCT00079859 | Phase 2 | Oct 1, 2003 | Medical Research Laboratories International |
| NCT00079846 | Phase 2 | Sep 1, 2003 | Medical Research Laboratories International |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Medical Research Laboratories International | For profit | 3 | 3 | 1 | 2003 |
1 organizations
Page 1 / 1